Anti-emetic drugs in anaesthesia

Anaesthesia and anti-cancer chemotherapeutic drugs.

PURPOSE OF REVIEW This is a review of anti-cancer chemotherapeutic drugs, describing their actions, interactions, and toxicity with a particular focus on the relevance for the anaesthetist. RECENT FINDINGS Anti-cancer chemotherapeutics have a vast array of adverse effects, some of which, i.e. cardiac and pulmonary toxicity, are of particular anaesthesiological relevance. Recently it has been ...

Spectrophotometric methods for the determination of anti-emetic drugs in bulk and in pharmaceutical preparations.

Four rapid, simple, reproducible and sensitive methods (A-D) for assaying domperidone (I) and metoclopramide (II) in a bulk sample and in dosage forms were investigated. The first and second methods, A and B, are based on the oxidation of I and/or II by Fe3+ in the presence of o-phenanthroline (o-phen) or bipyridyl (bipy). The formation of tris-complex upon reactions with Fe3+-o-phen and/or Fe3...

Improving the quality of anti-emetic therapy.

The outcome of anti-emetic therapy (AT) to women with gynaecological cancer receiving chemotherapy, in total 552 courses, was registered for a 1-year period. A quality improvement (QI) programme was established, based on three standardized AT regimens. Evaluation and documentation of AT effects were performed by the patients themselves, reporting the number of emetic episodes and degree of naus...

Incidence of postoperative nausea and emetic episodes after xenon anaesthesia compared with propofol-based anaesthesia.

BACKGROUND Xenon has been proved to be safe and efficacious for general anaesthesia in numerous trials. In addition, experimental studies demonstrate that xenon inhibits the 5-hydroxytryptamine type 3 (5-HT(3)) receptor. As 5-HT(3) receptor antagonists are known to decrease postoperative nausea and vomiting (PONV) to an extent comparable with a propofol-based total i.v. technique, we tested the...

Anti-emetic trials in oncology: What should be done next?